IP Library › Granted Patent US 12,415,856
Granted Patent B2
US 12,415,856 · App. 18/165,515 · Granted Sep 16, 2025

EGFR x CD28 multispecific antibodies

Inventors: Dimitris Skokos (New York, NY); Andrew J. Murphy (Tarrytown, NY); George D. Yancopoulos (Yorktown Heights, NY); Chia-yang Lin (Scarsdale, NY); Lauric Haber (Rye Brook, NY)
Assignee: Regeneron Pharmaceuticals, Inc.
C07K16/2818A61K9/0019A61K39/3955A61K45/06A61P35/00C07K16/2863C12N5/0682A61K2039/505C07K2317/31C07K2317/565C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,415,856
App. No.
18/165,515
Granted
Sep 16, 2025
Kind
B2
Abstract

The present invention provides multispecific antibodies that bind to EGFR and CD28 (EGFR×CD28) as well as anti-EGFR antibodies. Such antibodies may be combined with a further therapeutic agent such as an anti-PD1 antibody. Methods for treating cancers (e.g., EGFR-expressing cancer) by administering the antibodies (e.g., and combinations thereof with anti-PD1) are also provided. The EGFR×CD28 antibodies of the present invention embody a tumor-targeted immunotherapeutic modality combined with PD-1 inhibition. These bispecific antibodies bind a tumor-specific antigen (TSA) (EGFR) with one arm and the co-stimulatory receptor, CD28, on T-cells with the other arm. Combination therapy with PD-1 inhibitors specifically potentiated intra-tumoral T cell activation, promoting an effector memory-like T cell phenotype without systemic cytokine secretion in a variety of syngeneic and human tumor xenograft models. Combining this class of CD28-co-stimulatory bispecific antibodies with the clinically validated anti-PD-1 treatment provides a well-tolerated antibody therapy with markedly enhanced anti-tumor efficacy.

Claims (18)

1. A bispecific antigen-binding molecule comprising a first antigen-binding domain that specifically binds human CD28, and a second antigen-binding domain that specifically binds human EGFR,

(a) wherein the first antigen-binding domain that specifically binds human CD28 comprises three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) and three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3),

wherein the HCDR1 of the first antigen-binding domain comprises an amino acid sequence of SEQ ID NO: 12; the HCDR2 of the first antigen-binding domain comprises an amino acid sequence of SEQ ID NO: 6; the HCDR3 of the first antigen-binding domain comprises an amino acid sequence of SEQ ID NO: 14, the LCDR1 of the first antigen-binding domain comprises an amino acid sequence SEQ ID NO: 18, the LCDR2 of the first antigen-binding domain comprises the amino acid sequence GAS, and the LCDR3 of the first antigen-binding domain comprises an amino acid sequence SEQ ID NO: 22; and

(b) wherein the second antigen-binding domain that specifically binds human EGFR comprises three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) and three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3),

wherein the HCDR1 of the second antigen-binding domain comprises an amino acid sequence of SEQ ID NO: 52, the HCDR2 of the second antigen-binding domain comprises an amino acid sequence of SEQ ID NO: 54, the HCDR3 of the second antigen-binding domain comprises an amino acid sequence of SEQ ID NO: 56, the LCDR1 of the second antigen-binding domain comprises an amino acid sequence of SEQ ID NO: 18, the LCDR2 of the second antigen-binding domain comprises the amino acid sequence GAS, and the LCDR3 of the second antigen-binding domain comprises an amino acid sequence of SEQ ID NO: 22.

2. The bispecific antigen-binding molecule of claim 1 ,

wherein the first antigen-binding domain comprises a heavy chain variable region (HCVR) comprising SEQ ID NO: 10, and a light chain variable region (LCVR) comprising SEQ ID NO: 16; and

wherein the second antigen-binding domain comprises a HCVR comprising SEQ ID NO: 50, and a LCVR comprising SEQ ID NO: 16.

3. The bispecific antigen-binding molecule of claim 1 , wherein the antigen-binding molecule binds human cells expressing human CD28 and cynomolgus monkey cells expressing cynomolgus CD28.

4. The bispecific antigen-binding molecule of claim 1 , wherein the antigen-binding molecule induces T-cell mediated cytotoxicity of human cancer cells.

5. The bispecific antigen-binding molecule of claim 4 , wherein the cancer cells express EGFR.

6. The bispecific antigen-binding molecule of claim 4 , wherein the cancer is selected from the group consisting of esophageal carcinoma, lung squamous cell carcinoma, lung adenocarcinoma, cervical squamous cell carcinoma, endometrial adenocarcinoma, bladder urothelial carcinoma, lung cancer, non-small cell lung cancer, colorectal cancer, rectal cancer, endometrial cancer, skin cancer, head & neck squamous cell carcinoma, brain cancer, glioblastoma multiforme, breast cancer, gastroesophageal cancer, gastroesophageal adenocarcinoma, prostate cancer and ovarian cancer.

7. The bispecific antigen-binding molecule of claim 1 , that is a bispecific antibody, wherein:

(a) the first antigen-binding domain that specifically binds human CD28 comprises a heavy chain comprising the sequence of SEQ ID NO: 26, and a light chain comprising the sequence of SEQ ID NO: 28; and

(b) the second antigen-binding domain that specifically binds human EGFR comprises a heavy chain comprising the sequence of SEQ ID NO: 58, and a light chain comprising the sequence of SEQ ID NO: 28.

8. The bispecific antigen-binding molecule of claim 1 that is a bispecific antibody comprising a heavy chain of IgG1 isotype.

9. The bispecific antigen-binding molecule of claim 1 that is a bispecific antibody comprising a heavy chain of IgG4 isotype.

10. A pharmaceutical composition comprising the bispecific antigen-binding molecule of claim 1 and a pharmaceutically acceptable carrier or diluent.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2023
From: SKOKOS, DIMITRIS; MURPHY, ANDREW J.; YANCOPOULOS, GEORGE D.; LIN, CHIA-YANG; HABER, LAURIC
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 064067/0884 →
Continuity (3)
Continuation 16825179 · Mar 20, 2020
Provisional Application 62822124 · Mar 22, 2019
Related Publication 20230322927A1 · Oct 12, 2023
References Cited (32)
US 10179819B2 · Kirshner et al. · 2019 [cited by applicant]
US 11912767B2 · Skokos · 2024 [cited by examiner]
US 20050136050A1 · Kufer et al. · 2005 [cited by applicant]
US 20140243504A1 · Davis et al. · 2014 [cited by applicant]
US 20200239576A1 · Murphy et al. · 2020 [cited by applicant]
US 20200299388A1 · Skokos et al. · 2020 [cited by applicant]
CN 104411722A · 2015 [cited by applicant]
CN 104558190A · 2015 [cited by applicant]
CN 106632681A · 2017 [cited by applicant]
JP 2015502373A · 2015 [cited by applicant]
WO 2007042261A2 · 2007 [cited by applicant]
WO 2013092001A1 · 2013 [cited by applicant]
WO 2014004427A2 · 2014 [cited by applicant]
Che et al., Preparation and Preliminary Investigation of Function of Anti-EGFR/CD3 Bispecific Antibody. J Fujian Med Univ. Dec. 28, 2017;51(6):369-74. [cited by applicant]
Jung et al., Local immunotherapy of glioma patients with a combination of 2 bispecific antibody fragments and resting autologous lymphocytes: evidence for in situ t-cell activation and therapeutic efficacy. Int J Cancer… [cited by applicant]
Kussie et al., A single engineered amino acid substitution changes antibody fine specificity. J Immunol. Jan. 1, 1994;152(1):146-52. [cited by applicant]
Li et al., Advances in the Study of Bispecific Antibody and Its Application in Tumor Diagnosis and Treatment. J Med Molec Bio. May 30, 2005;3:233-5. [cited by applicant]
Lum et al., Development and prospects for bispecific antibody-based therapeutics in cancer and other applications. Expert Opin Drug Discov. Sep. 2008;3(9):1081-97. [cited by applicant]
Morris, Epitope Mapping of Protein Antigens by Competition ELISA. The Protein Protocols Handbook. Humana Press, Jan. 1, 1996; 595-600. [cited by applicant]
Panka et al., Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies. Proc Natl Acad Sci U S A. May 1988;85(9):3080-4. [cited by applicant]
Pfosser et al., Role of target antigen in bispecific-antibody-mediated killing of human glioblastoma cells: a pre-clinical study. Int J Cancer. Feb. 9, 1999;80(4):612-6. [cited by applicant]
Rudikoff et al., Single amino acid substitution altering antigen-binding specificity. Proc Natl Acad Sci U S A. Mar. 1982;79(6):1979-83. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2020/023857, dated Jul. 3, 2020, 10 pages. [cited by applicant]
Beyersdorf et al., Superagonistic anti-CD28 antibodies: potent activators of regulatory T cells for the therapy of autoimmune diseases. Ann Rheum Dis. Nov. 2005;64 Suppl 4(Suppl 4):iv91-5. [cited by applicant]
Bostrom et al., Improving antibody binding affinity and specificity for therapeutic development. Methods Mol Biol. 2009;525:353-76, xiii. [cited by applicant]
Dondelinger et al., Understanding the Significance and Implications of Antibody Numbering and Antigen-Binding Surface/Residue Definition. Front Immunol. Oct. 16, 2018;9:2278, 15 pages. [cited by applicant]
Gonzales et al., Minimizing the immunogenicity of antibodies for clinical application. Tumour Biol. Jan.-Feb. 2005;26 (1):31-43. [cited by applicant]
Hunig et al., The rise and fall of the CD28 superagonist TGN1412 and its return as TAB08: a personal account. Febs J. Sep. 2016;283(18):3325-34. [cited by applicant]
Kunik et al., Structural consensus among antibodies defines the antigen binding site. PLoS Comput Biol. 2012;8(2): e1002388, 12 pages. [cited by applicant]
O'Neil et al., An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies. Mol Cancer Ther. Jun. 2016;15(6):1155-62. [cited by applicant]
Vajdos et al., Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis. J Mol Biol. Jul. 5, 2002;320(2):415-28. [cited by applicant]
Wark et al., Latest technologies for the enhancement of antibody affinity. Adv Drug Deliv Rev. Aug. 7, 2006;58 (5-6):657-70. [cited by applicant]